دورية أكاديمية
Targeting serotonin receptor 2B inhibits TGFβ induced differentiation of human vascular smooth muscle cells.
العنوان: | Targeting serotonin receptor 2B inhibits TGFβ induced differentiation of human vascular smooth muscle cells. |
---|---|
المؤلفون: | Wenglén C; ANAMAR, Lund, Sweden., Demirel I; Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Eremo AG; Department of Clinical Research Laboratory, Faculty of Medicine, and Health, Örebro University, Örebro, Sweden., Grenegård M; Cardiovascular Research Centre, School of Medical Sciences, Örebro University, Örebro, Sweden., Paramel GV; Cardiovascular Research Centre, School of Medical Sciences, Örebro University, Örebro, Sweden. Electronic address: geena.paramel@oru.se. |
المصدر: | European journal of pharmacology [Eur J Pharmacol] 2023 Apr 05; Vol. 944, pp. 175570. Date of Electronic Publication: 2023 Feb 11. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2005- : Amsterdam : Elsevier Science Original Publication: Amsterdam, North Holland Pub. Co. |
مواضيع طبية MeSH: | Atherosclerosis*/pathology , Transforming Growth Factor beta*/metabolism, Humans ; Carrier Proteins/metabolism ; Cell Differentiation ; Cells, Cultured ; Muscle, Smooth, Vascular ; Myocytes, Smooth Muscle/metabolism ; Receptor, Serotonin, 5-HT2B/metabolism ; Transforming Growth Factor beta1/metabolism |
مستخلص: | Vascular Smooth Muscle Cells (VSMCs) are known to be the key drivers of intimal thickening which contribute to early progression of atherosclerosis. VSMCs are the major producers of extracellular matrix within the vessel wall and in response to atherogenic stimuli they could modify the type of matrix proteins produced. Serotonin receptor 2B (5-HT Competing Interests: Declaration of competing interest C.W. declares employment by AnaMar AB, a company developing 5-HT2B receptor antagonists for therapeutic purposes. (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.) |
فهرسة مساهمة: | Keywords: Atherosclerosis; Differentiation; Serotonin receptor; Smad; TGFβ; Vascular smooth muscle cells |
المشرفين على المادة: | 0 (Carrier Proteins) 0 (Receptor, Serotonin, 5-HT2B) 0 (Transforming Growth Factor beta) 0 (Transforming Growth Factor beta1) |
تواريخ الأحداث: | Date Created: 20230213 Date Completed: 20230307 Latest Revision: 20230307 |
رمز التحديث: | 20240628 |
DOI: | 10.1016/j.ejphar.2023.175570 |
PMID: | 36781042 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1879-0712 |
---|---|
DOI: | 10.1016/j.ejphar.2023.175570 |